Objectives: Osteoarthritis (OA) is a joint failure and OA is the most frequent chronic joint disease causing pain and disability. Where all the structures of joints have undergone pathological changes and they are hyaline articular cartilage loss which may be focal or non-uniform, initially it will be focal then spread all over non-uniformly. Non-Steroidal Anti Inflammatory Drugs are the mainstay of medical management of OA. Increased in reports suggests that GIT adverse effect with old NSAID’s and cardiovascular effects with selective cyclooxygenase-2 (COX-2) inhibitors had precipitated to chase for better NSAID’s with minimal adverse effects. The current study compares the clinical effectiveness and safety of newer NSAID’s, Etoricoxib, Lornoxicam, to Diclofenac which has been standard therapy in patients of OA of the knee joint.
Material ; Methods: The current study was randomized, prospective, open-label, parallel group study conducted in 120 patients with OA of the knee joint diagnosed according to American College of Rheumatology criteria. After obtaining the informed consent, they were randomized in three groups of 40 patients each who received tablet Etoricoxib 120mg BID, tablet Lornoxicam 16mg BID, tablet Diclofenac 50mg TID respectively. The duration of the study was 12 weeks. Data were calculated, tabulated and analyzed using analysis of variance (ANOVA) test, and level of significance was determined by its P value.
Results: After 12 weeks of treatment, the severity of pain and functional indices in terms of visual analog scale and Western Ontario and McMaster Universities Osteoarthritis score were significantly better (P ; 0.05) in Etoricoxib group as compared to Lornoxicam or Diclofenac group along with a lesser rate of adverse effects.
Conclusion: It was concluded that Etoricoxib was more effective and tolerated NSAID than Lornoxicam and Diclofenac in the treatment of knee joint OA.
Keywords: Etoricoxib, Lornoxicam, Diclofenac, VAS, WOMAC Score.